Current Role of Surgery in the Management of Oropharyngeal Cancer

Wojciech Golusiński, Ewelina Golusińska-Kardach, Wojciech Golusiński, Ewelina Golusińska-Kardach

Abstract

In the last few decades, the surgical treatment of oropharyngeal squamous cell carcinoma (OPSCC) has undergone enormous changes. Until the 1990s, open surgery was the primary treatment for OPSCC. However, due to the potentially severe functional morbidity of this approach, open surgery was largely displaced by concurrent chemoradiotherapy (CRT) in the 1990s. At the same time, new, less-invasive surgical approaches such as transoral surgery with monopolar cautery began to emerge, with the potential to reduce functional morbidity and avoid the late-onset toxicity of CRT. More recently, the growing incidence of HPV-positive disease has altered the patient profile of OPSCC, as these patients tend to be younger and have a better long-term prognosis. Consequently, this has further bolstered interest in minimally-invasive techniques to de-intensify treatment to reduce long-term toxicity and treatment-related morbidity. In this context, there has been a renewed interest in the primary surgery, which allows for accurate pathologic staging and thus-potentially-de-intensification of postoperative CRT. The continuous advances in minimally-invasive surgical approaches, including transoral laser microsurgery (TLM) and transoral robotic surgery (TORS), have also altered the surgical landscape. These minimally-invasive approaches offer excellent functional outcomes, without the severe toxicity associated with intensive CRT, thus substantially reducing treatment-related morbidity. In short, given the increasing prevalence of HPV-positive OPSCC, together with the severe long-term sequela of aggressive CRT, surgery appears to be recapturing its previous role as the primary treatment modality for this disease. While a growing body of evidence suggests that TLM and TORS offer oncologic outcomes that are comparable to CRT and open surgery, many questions remain due to the lack of prospective data. In the present review, we explore the emerging range of surgical options and discuss future directions in the treatment of OPSCC, including the most relevant clinical trials currently underway.

Keywords: TLM; TORS; cancer; oropharynx; surgery.

Figures

Figure 1
Figure 1
Scheme of treatment of oropharyngeal cancer.

References

    1. Baskin RM, Boyce BJ, Amdur R, Mendenhall WM, Hitchcock K, Silver N, et al. . Transoral robotic surgery for oropharyngeal cancer : patient selection and special considerations. Cancer Manag Res. (2018) 10:839–46. 10.2147/CMAR.S118891
    1. Dowthwaite SA, Franklin JH, Palma DA, Fung K, Yoo J, Nichols AC. The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature. ISRN Oncol. (2012) 2012:1–14. 10.5402/2012/945162
    1. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. (2011) 100:33–40. 10.1016/j.radonc.2011.05.036
    1. Tschudi D, Stoeckli S, Schmid S. Quality of life after different treatment modalities for carcinoma of the oropharynx. Laryngoscope. (2003) 113:1949–54. 10.1097/00005537-200311000-00018
    1. Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, et al. . Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. (2009) 73:410–5. 10.1016/j.ijrobp.2008.04.048
    1. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. . Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. (2008) 26:3582–9. 10.1200/JCO.2007.14.8841
    1. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. (2014) 50:380–6. 10.1016/j.oraloncology.2013.12.019
    1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. (2010) 363:24–35. 10.1056/NEJMoa0912217
    1. Mydlarz WK, Chan JYK, Richmon JD. The role of surgery for HPV-associated head and neck cancer. Oral Oncol. (2015) 51:305–13. 10.1016/j.oraloncology.2014.10.005
    1. Speel EJM. HPV integration in head and neck squamous cell carcinomas: cause and consequence. In: Golusinski W, Leemans CR, Dietz A, editors. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches sur le Cancer. Cham: Springer International Publishing; (2017). p. 57–72. 10.1007/978-3-319-43580-0_4
    1. Lim GC, Holsinger FC, Li RJ. Transoral endoscopic head and neck surgery: the contemporary treatment of head and neck cancer. Hematol Oncol Clin North Am. (2015) 29:1075–92. 10.1016/j.hoc.2015.08.001
    1. Mirghani H, Blanchard P. Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? Clin Transl Radiat Oncol. (2018) 8:4–11. 10.1016/J.CTRO.2017.10.005
    1. Fischer CA, Zlobec I, Green E, Probst S, Storck C, Lugli A, et al. . Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer. (2010) 126:1256–62. 10.1002/ijc.24842
    1. de Almeida JR, Li R, Magnuson JS, Smith RV, Moore E, Lawson G, et al. Oncologic outcomes after transoral robotic surgery. JAMA Otolaryngol Neck Surg. (2015) 141:1043 10.1001/jamaoto.2015.1508
    1. Dziegielewski PT, Teknos TN, Durmus K, Old M, Agrawal A, Kakarala K, et al. . Transoral Robotic Surgery for Oropharyngeal Cancer. JAMA Otolaryngol Neck Surg. (2013) 139:1099. 10.1001/jamaoto.2013.2747
    1. Röösli C, Tschudi DC, Studer G, Braun J, Stoeckli SJ. Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx. Laryngoscope. (2009) 119:534–40. 10.1002/lary.20033
    1. Golusinski W. The role of conventional surgery in oropharyngeal cancer. Recent Results Cancer Res. (2017) 206:185–95. 10.1007/978-3-319-43580-0_14
    1. Moncrieff M, Sandilla J, Clark J, Clifford A, Shannon K, Gao K, et al. . Outcomes of Primary surgical treatment of T1 and T2 carcinomas of the oropharynx. Laryngoscope. (2009) 119:307–11. 10.1002/lary.20053
    1. Tateya I, Shiotani A, Satou Y, Tomifuji M, Morita S, Muto M, et al. . Transoral surgery for laryngo-pharyngeal cancer - The paradigm shift of the head and cancer treatment. Auris Nasus Larynx. (2016) 43:21–32. 10.1016/j.anl.2015.06.013
    1. Arens C. Transoral treatment strategies for head and neck tumors. GMS Curr Top Otorhinolaryngol Head Neck Surg. (2012) 11:Doc05. 10.3205/cto000087
    1. Kass J, Pool C, Teng M, Miles B, Genden E. Initial experience using transoral robotic surgery for advanced-Stage (T3) tumors of the head and neck. Int J Radiat Oncol. (2016) 94:899 10.1016/j.ijrobp.2015.12.106
    1. Weinstein GS, O'Malley BW, Cohen MA, Quon H. Transoral robotic surgery for advanced oropharyngeal carcinoma. Arch Otolaryngol Neck Surg. (2010) 136:1079. 10.1001/archoto.2010.191
    1. Lacocourreye O, Hans S, Ménard M, Garcia D, Brasnu D, Holsinger FC. Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region. Arch Otolaryngol Head Neck Surg. (2005) 131:592–9. 10.1001/archotol.131.7.592
    1. Upile NS, Shaw RJ, Jones TM, Goodyear P, Liloglou T, Risk JM, et al. . Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related. Laryngoscope. (2014) 124:2739–44. 10.1002/lary.24828
    1. Moore EJ, Hinni ML. Critical review: transoral laser microsurgery and robotic-assisted surgery for oropharynx cancer including human papillomavirus–related cancer. Int J Radiat Oncol Biol Phys. (2013) 85:1163–7. 10.1016/j.ijrobp.2012.08.033
    1. Howard J, Masterson L, Rc D, Riffat F, Benson R, Jefferies S, et al. . Minimally invasive surgery versus radiotherapy / chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Cochrane Database Syst Rev. (2016) 12:CD010963. 10.1002/14651858.CD010963.pub2
    1. Bhayani MK, Holsinger FC, Lai SY. A shifting paradigm for patients with head and neck cancer: transoral robotic surgery (TORS)|cancer network. Oncology (Williston Park). (2010) 24:1010–5.
    1. Lörincz BB, Jowett N, Knecht R. Decision management in transoral robotic surgery: Indications, individual patient selection, and role in the multidisciplinary treatment for head and neck cancer from a European perspective. Head Neck. (2016) 38:E2190–6. 10.1002/hed.24059
    1. Weinstein GS, O'Malley BW, Hockstein NG. Transoral robotic surgery: supraglottic laryngectomy in a canine model. Laryngoscope. (2005) 115:1315–9. 10.1097/01.MLG.0000170848.76045.47
    1. McLeod IK, Melder PC. Da Vinci robot-assisted excision of a vallecular cyst: a case report. Ear Nose Throat J. (2005) 84:170–2.
    1. Hammoudi K, Pinlong E, Kim S, Bakhos D, Morinière S. Transoral robotic surgery versus conventional surgery in treatment for squamous cell carcinoma of the upper aerodigestive tract. Head Neck. (2015) 37:1304–9. 10.1002/hed.23752
    1. Baliga S, Jiang J, Mehta V, Guha C, Kalnicki S, Smith RV, et al. . Utilization of Transoral Robotic Surgery (TORS) in patients with oropharyngeal squamous cell carcinoma and its impact on survival and use of chemotherapy. Oral Oncol. (2018) 86:75–80. 10.1016/j.oraloncology.2018.06.009
    1. Kass JI, Giraldez L, Gooding W, Choby G, Kim S, Miles B, et al. . Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma. Head Neck. (2016) 38:3–7. 10.1002/HED
    1. Dabas S, Gupta K, Ranjan R, Sharma AK, Shukla H, Dinesh A. Oncological outcome following de-intensification of treatment for stage I and II HPV negative oropharyngeal cancers with transoral robotic surgery (TORS): a prospective trial. Oral Oncol. (2017) 69:80–3. 10.1016/j.oraloncology.2017.04.010
    1. Moore EJ, Pa-c EJM, Abel KM, Price DL, Lohse CM, Kerry MS, et al. . Transoral robotic surgery for oropharyngeal carcinoma : surgical margins and oncologic outcomes. Head Neck. (2018) 40:747–55. 10.1002/hed.25055
    1. Doazan M, Hans S, Moriniére S, Lallemant B, Vergez S, Aubry K, et al. . Oncologic outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: results of the French Robotic Surgery Group of GETTEC. Head Neck. (2018) 40:2050–9. 10.1002/hed.25199
    1. Min Y, Min C, Cha D, Kim S. The long-term oncological and functional outcomes of transoral robotic surgery in patients with hypopharyngeal cancer. Oral Oncol. (2017) 71:138–43. 10.1016/j.oraloncology.2017.06.016
    1. Weinstein GS, Quon H, Newman HJ, Chalian JA, Malloy K, Lin A, et al. . Transoral robotic surgery alone for oropharyngeal cancer. Arch Otolaryngol Neck Surg. (2012) 138:628. 10.1001/archoto.2012.1166
    1. Garas G, Arora A, Arora A. Robotic head and neck surgery: history, technical evolution and the future. Orl. (2018) 80:1–8. 10.1159/000489464
    1. Pollei TR, Hinni ML, Moore EJ, Hayden RE, Olsen KD, Casler JD, et al. . Analysis of postoperative bleeding and risk factors in transoral surgery of the oropharynx. JAMA Otolaryngol Neck Surg. (2013) 139:1212. 10.1001/jamaoto.2013.5097
    1. Chia SH, Gross ND, Richmon JD. Surgeon Experience and Complications with Transoral Robotic Surgery (TORS). Otolaryngol Neck Surg. (2013) 149:885–92. 10.1177/0194599813503446
    1. Zenga J, Suko J, Kallogjeri D, Pipkorn P, Nussenbaum B, Jackson RS. Postoperative hemorrhage and hospital revisit after transoral robotic surgery. Laryngoscope. (2017) 127:2287–92. 10.1002/lary.26626
    1. Mandal R, Duvvuri U, Ferris RL, Kaffenberger TM, Choby GW, Kim S. Analysis of post-transoral robotic-assisted surgery hemorrhage: frequency, outcomes, and prevention. Head Neck. (2015) 38:E776–82. 10.1002/hed.24101
    1. Hay A, Migliacci J, Zanoni DK, Boyle JO, Singh B, Wong RJ, et al. . Complications following transoral robotic surgery (TORS): a detailed institutional review of complications. Oral Oncol. (2017) 67:160–6. 10.1016/j.oraloncology.2017.02.022
    1. Aubry K, Vergez S, de Mones E, Moriniere S, Choussy O, Malard O, et al. . Morbidity and mortality revue of the French group of transoral robotic surgery: a multicentric study. J Robot Surg. (2016) 10:63–7. 10.1007/s11701-015-0542-z
    1. Albergotti WG, Gooding WE, Kubik MW, Geltzeiler M, Kim S, Duvvuri U, et al. . Assessment of surgical learning curves in transoral robotic surgery for squamous cell carcinoma of the oropharynx. JAMA Otolaryngol Head Neck Surg. (2017) 143:542–8. 10.1001/jamaoto.2016.4132
    1. Durmus K, Kucur C, Uysal IO, Dziegielewski PT, Ozer E. Feasibility and clinical outcomes of transoral robotic surgery and transoral robot-assisted carbon dioxide laser for hypopharyngeal carcinoma. J Craniofac Surg. (2015) 26:235–7. 10.1097/SCS.0000000000001185
    1. Desai SC, Sung C-K, Jang DW, Genden EM. Transoral robotic surgery using a carbon dioxide flexible laser for tumors of the upper aerodigestive tract. Laryngoscope. (2008) 118:2187–9. 10.1097/MLG.0b013e31818379e4
    1. Rich JT, Milov S, Lewis JS, Thorstad WL, Adkins DR, Haughey BH. Transoral laser microsurgery (TLM) ± adjuvant therapy for advanced stage oropharyngeal cancer. Laryngoscope. (2009) 119:1709–19. 10.1002/lary.20552
    1. Holsinger FC, Ferris RL. Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: robotics, lasers, and clinical trials. J Clin Oncol. (2015) 33:3285–92. 10.1200/JCO.2015.62.3157
    1. Arora A, Kotecha J, Acharya A, Garas G, Darzi A, Davies DC, et al. . Determination of biometric measures to evaluate patient suitability for transoral robotic surgery. Head Neck. (2015) 37:1254–60. 10.1002/hed.23739
    1. Weinstein GS, O'Malley BW, Rinaldo A, Silver CE, Werner JA, Ferlito A. Understanding contraindications for transoral robotic surgery (TORS) for oropharyngeal cancer. Eur Arch Oto-Rhino-Laryngology. (2015) 272:1551–2. 10.1007/s00405-014-3331-9
    1. Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, et al. . NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Cancer Netw. (2017) 15:761–70. 10.6004/jnccn.2017.0101
    1. Monnier Y, Simon C. Surgery versus radiotherapy for early oropharyngeal tumors: a never-ending debate. Curr Treat Options Oncol. (2015) 16:42. 10.1007/s11864-015-0362-4
    1. Mehanna H, Evans M, Beasley M, Chatterjee S, Dilkes M, Homer J, et al. . Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. (2016) 130:S90–6. 10.1017/S0022215116000505
    1. Morisod B, Simon C. Meta-analysis on survival of patients treated with transoral surgery versus radiotherapy for early-stage squamous cell carcinoma of the oropharynx. Head Neck. (2016) 38:E2143–50. 10.1002/hed.23995
    1. Díaz-Molina JP, Rodrigo JP, Alvarez-Marcos C, Blay P, de la Rúa A, Estrada E, et al. . Functional and oncological results of non-surgical vs surgical treatment in squamous cell carcinomas of the oropharynx. Acta otorrinolaringológica española (2012). 63:348–54. 10.1016/j.otorri.2012.02.005
    1. Zenga J, Wilson M, Adkins DR, Gay HA, Haughey BH, Kallogjeri D, et al. . Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Neck Surg. (2015) 141:1118. 10.1001/jamaoto.2015.0764
    1. Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, et al. . Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a united states multicenter study. Head Neck. (2011) 33:1683–94. 10.1002/hed.21669
    1. Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, et al. . Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck. (2012) 35:23173. 10.1002/hed.23173
    1. White HN, Moore EJ, Rosenthal EL, Carroll WR, Olsen KD, Desmond RA, et al. . Transoral robotic-assisted surgery for head and neck squamous cell carcinoma. Arch Otolaryngol Neck Surg. (2010) 136:1248. 10.1001/archoto.2010.216
    1. Cohen MA, Weinstein GS, O'Malley BW, Feldman M, Quon H. Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck. (2011) 33:573–80. 10.1002/hed.21500
    1. Hutcheson KA, Holsinger FC, Kupferman ME, Lewin JS. Functional outcomes after TORS for oropharyngeal cancer: a systematic review. Eur Arch Oto-Rhino-Laryngology. (2015) 272:463–71. 10.1007/s00405-014-2985-7
    1. Hamoir M, Schmitz S, Suarez C, Strojan P, Hutcheson KA, Rodrigo JP, et al. . The current role of salvage surgery in recurrent head and neck squamous cell carcinoma. Cancers. (2018) 10:E267. 10.3390/cancers10080267
    1. Mehanna H, Kong A, Ahmed S. Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. (2016) 130:S181–90. 10.1017/S002221511600061X
    1. Mandapathil M, Roessler M, Werner JA, Silver CE, Rinaldo A, Ferlito A. Salvage surgery for head and neck squamous cell carcinoma. Eur Arch Oto-Rhino-Laryngol. (2014) 271:1845–50. 10.1007/s00405-014-3043-1
    1. White H, Ford S, Bush B, Holsinger FC, Moore E, Ghanem T, et al. . Salvage surgery for recurrent cancers of the oropharynx. JAMA Otolaryngol Neck Surg. (2013) 139:773. 10.1001/jamaoto.2013.3866
    1. Meulemans J, Vanclooster C, Vauterin T, D'heygere E, Nuyts S, Clement PM, et al. . Up-front and salvage transoral robotic surgery for head and neck cancer: a belgian multicenter retrospective case series. Front Oncol. (2017) 7:15. 10.3389/fonc.2017.00015
    1. Paleri V, Fox H, Coward S, Ragbir M, McQueen A, Ahmed O, et al. . Transoral robotic surgery for residual and recurrent oropharyngeal cancers: exploratory study of surgical innovation using the IDEAL framework for early-phase surgical studies. Head Neck. (2018) 40:512–25. 10.1002/hed.25032
    1. Ibrahim AS, Civantos FJ, Leibowitz JM, Thomas GR, Arnold DJ, Franzmann EJ, et al. . Meta-analysis comparing outcomes of different transoral surgical modalities in management of oropharyngeal carcinoma. Head Neck. (2019) 10.1002/hed.25647.[Epub ahead of print]
    1. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. . Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. (2019) 393:51–60. 10.1016/S0140-6736(18)32752-1
    1. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. . Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. (2019) 393:40–50. 10.1016/S0140-6736(18)32779-X

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever